🇺🇸 insulin NPH in United States
215 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 215
Most-reported reactions
- Diarrhoea — 29 reports (13.49%)
- Dyspnoea — 26 reports (12.09%)
- Hypoglycaemia — 23 reports (10.7%)
- Nausea — 22 reports (10.23%)
- Pneumonia — 22 reports (10.23%)
- Blood Glucose Increased — 21 reports (9.77%)
- Malaise — 20 reports (9.3%)
- Vomiting — 19 reports (8.84%)
- Asthenia — 17 reports (7.91%)
- Confusional State — 16 reports (7.44%)
Other Diabetes approved in United States
Frequently asked questions
Is insulin NPH approved in United States?
insulin NPH does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for insulin NPH in United States?
Novo Nordisk A/S is the originator. The local marketing authorisation holder may differ — check the official source linked above.